78P - Immunotherapy enhanced by geroprotection: hormone-resistant prostate cancer (78P)

Date 08 December 2017
Event ESMO Immuno-Oncology Congress 2017
Session Lunch & Poster Display session
Topics Cancer in Special Situations
Central Nervous System Malignancies
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Eduardo Lasalvia-Prisco
Citation Annals of Oncology (2017) 28 (suppl_11): xi6-xi29. 10.1093/annonc/mdx711
Authors E.M. Lasalvia-Prisco1, C. Dau2, P. Goldschmidt3, F. Galmarini4, J. Vazquez2, E.E. Lasalvia-Galante2
  • 1R&d, Interdoctors-Telemedical Organization, 11200 - Montevideo/UY
  • 2R&d, Interdoctors-Telemedical Organization-Uruguay, 11200 - Montevideo/UY
  • 3R&d, Interdoctors-Telemedical Organization-France, 75001 - Paris/FR
  • 4R&d, Interdoctors-Telemedical Organization-Argentina, 1043 - Buenos Aires/AR

Abstract

Background

Some tumor molecules circulate in the blood, and in some cases, they are used as markers of the disease (CEA, PSA). Several authors have reported the efficacy of some of these molecules for immunotherapy, which is the case of the Autologous Hemoderivative Cancer Vaccine (AHCV) that uses a thermostable molecular fraction of autologous blood as intradermal immunogen, and an intradermal way for immunization. We are searching adjuvant procedures to improve such immunotherapy. In this study, we tested AHCV in human hormone-refractory prostate cancer, and as adjuvant, we used metformin that has been identified as a geroprotector with regenerative activity of immunity, depressed by the immunosenescence phenomenon prevalent in aged patients.

Methods

From the data included in published trials that tested AHCV, 45 records were reviewed for this analysis, all patients with hormone-resistant prostate cancer in PSA progression, 60-85 years old, diabetes type 2, treated with metformin. These were divided into3 groups of 15 records each, patients receiving 0, 5 and 10 months of metformin 850 to 1000 mg/day, respectively. All groups had received monthly for one year vaccination with AHCV as was reported. Follow-up of records was for 12 months. Assessments: At the beginning and at the end of the 1-yr follow-up, evaluations were performed: PSA in blood by standard immunochemical method, glycosylated hemoglobin and ferritin, two biomarkers of aging mechanisms (glycation and inflammation), and diameter of intradermal papular response to vaccination measured 48 hours after inoculation. The variations of such assessments were registered.

Results

Shown in Table.Table: 78P

Metformin Pre-treatment0 month5 months10 months
1 yr Variation Glycosylated Hemoglobin mmol/mol+0.8 (0.3 - 1.1)+0.5 (0.4 - 0.9)+0.1 (0.06 - 0.18)
1 yr Variation Ferritin ng/ml+11.2 (10.2 - 12.1)+8.6 (7.9 - 9.1)+3.2 (2.8 - 4.1)
1 yr Variation of Intradermal test 48 hs Diameter (mm)3.1 (2.8 – 3.4)5.5 (5.1 – 6.2)8.2 (7.4 – 8.8)3.5 (3.0 – 3.9)5.8 (5.3 – 6.4)8.8 (8.3 – 9.2)4.0 (3.6 – 4.5)6.1 (5.6 – 7.1)9.5 (9.0 – 9.9)
1 yr Variation of PSA (ng/ml)12.8 (12.1 – 13.4)12.6 (11.8 – 13.2)12.6 (11.4 – 13.4)11.4 (10.8 – 11.9)11.8 (11.0 – 12.4)11.9 (11.0 – 12.7)10.4 (9.8 – 11.1)10.1 (9.4 – 10.9)8.7 (7.9 – 9.4)

Conclusions

In hormone-resistant prostate cancer, the previously reported immunogenic activity of AHCV increases with metformin pretreatment in association with geroprotection, as estimated by biomarkers of aging.

Clinical trial identification

Records review.

Legal entity responsible for the study

Cooperative Research Group Interdoctors-Telemedical Organization

Funding

None

Disclosure

All authors have declared no conflicts of interest.